Thromboxane, prostacyclin, beta-thromboglobin, and diabetes mellitus

Area of Science:

• Endocrinology
• Hematology
• Pharmacology

Background:

• Noninsulin-dependent diabetes mellitus (NIDDM) is associated with metabolic dysregulation.
• Platelet hyperactivity, indicated by elevated thromboxane B2 (TXB2) and beta-thromboglobin (beta-TH), may contribute to complications in diabetes.
• The role of glycemic control in modulating platelet function in NIDDM requires further investigation.

Purpose of the Study:

• To investigate plasma levels of beta-thromboglobin (beta-TH), thromboxane B2 (TXB2), and 6-keto-prostaglandin F1-alpha in patients with NIDDM.
• To assess the impact of dietary treatment and glibenclamide administration on these markers and blood glucose levels.
• To explore the relationship between glycemic control and platelet activity in NIDDM.

Main Methods:

• Radioimmunoassay (RIA) was used to measure plasma concentrations of beta-TH, TXB2, and 6-keto-PGF1-alpha.
• Eight patients with newly detected hyperglycemia in NIDDM were studied.
• Measurements were taken before and after dietary intervention and glibenclamide treatment.

Main Results:

• Initial examination revealed elevated TXB2 and beta-TH levels, indicating platelet hyperactivity, alongside hyperglycemia.
• Following glibenclamide treatment, significant reductions in TXB2, beta-TH, and blood glucose levels were observed.
• No significant changes were noted in 6-keto-prostaglandin F1-alpha levels.

Conclusions:

• Diabetes mellitus is associated with hyperactivity of platelet aggregation.
• Effective control of blood glucose levels, as achieved with glibenclamide, attenuates platelet hyperactivity.
• Further research is needed to determine if the observed reduction in platelet hyperactivity is a direct effect of glucose lowering or a consequence of the drug's action.